Abstract library

33 results for "Dhall".
#2962 90Y- and/or 177Lu-DOTATOC Re-Challenge in Patients with Progressive Neuroendocrine Tumors
Introduction: Most patients treated with PRRT will eventually progress. Previous studies indicated that repeated PRRT is feasible and promising.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr. med. Susanne Aberle
Authors: Aberle S, Benz M, Grokovski R, Christ E, ...
#3044 Efficacy of Alkylating Agent Re-challenge after Therapeutic Pause in Metastatic Pancreatic Neuroendocrine Tumors (PanNET)
Introduction: Temozolomide (TMZ) and dacarbazine (DTIC) are alkylating agents (ALK) with antitumor efficacy in metastatic PanNET. Rechallenging ALK following prior efficacy is commonly performed but has not been evaluated.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Dr Louis de Mestier
#992 Phase 1 and Phase 2 Clinical Trials Investigating Targets Against the Molecular Hallmarks of Gastroenteropancreatic Neuroendocrine Tumors
Introduction: Recently there have been many advances in the diagnosis and treatment of gastroenteropancreatic neuroendocrine tumors (GEP NETs), accompanied by significant improvements in our understanding of GEP NET biology. A number of well-established or novel molecular hallmarks are involved in GEP NET tumorigenesis and may help in identifying potential diagnostic or therapeutic targets.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - Others
Presenting Author: Dr Gianluca Tamagno
#1222 The Clinical Utility of Blood Derived Gene Cluster Analysis of Neuroendocrine Tumors Using Neoplasia Hallmark Criteria
Introduction: We developed a multianalyte blood (51 transcript) assay (MAAA) for GEP-NETs with a sensitivity (98%) and specificity (97%).
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Biomarkers
Presenting Author: Professor Mark Kidd
Authors: Kidd M, Drozdov I, Modlin I, ...
Keywords: PCR
#607 Goblet Cell Carcinoma of the Appendix: Acute v. Chronic Presentations
Introduction: Goblet Cell Carcinomas (GCC) are a rare neuroendocrine tumor (NET) of the appendix.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Dr Ron Basuroy
#663 Comparing Chinese Pancreatic Neuroendocrine Tumors with Americans: Their Clinicopathological Features and Prognosis
Introduction: It is unknown if clin-patho features of PNET pts are different between China and USA, the largest country in the east and west, respectively.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Biomarkers
Presenting Author: Dr. X.W. Qiao
Authors: Qiao X W, Tang L, Zhu L M, Chen J, ...
#1349 Access to Care and Outcomes for Neuroendocrine Tumors: Does Socio-Economic Status Matter? A Population-Based Analysis.
Introduction: Neuroendocrine Tumors (NET) lack standardized care. Differences in socioeconomic status (SES) worsen the impact of non-standardized care.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Hallet Julie
#1350 Understanding a Neuroendocrine Tumors’ Impact on Health Systems: A Population-Based Economic Analysis of Patterns of Costs
Introduction: Little is known on resource utilization and health care costs in NET care.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Hallet Julie
Authors: Hallet J, Law C, Cheung M, Fischer H, ...
Keywords: costs, care patterns
#1352 Outcomes of Cytoreductive Surgery for Well-Differentiated Metastatic Neuroendocrine Tumors in the Setting of Extra-Hepatic Metastases
Introduction: Cytoreduction with extra-hepatic disease for neuroendocrine tumors (NET) remains controversial
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Surgical treatment
Presenting Author: Hallet Julie
#1716 Trans-Anal Minimally Invasive Surgery (TAMIS) for Completion Local Excision of Well-Differentiated Rectal Neuroendocrine Tumours.
Introduction: Rectal NETs (R-NETs) <2cm are often amenable to endoscopic resection, but initial resections are often incomplete, and extended monitoring or radical surgery may then be required. Trans-anal minimally invasive surgery (TAMIS) allows resection of rectal tumours while reducing surgical morbidity. Data on its use in R-NETs is scant.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Surgical treatment
Presenting Author: Dr David Chan
Authors: Chan D, Law C, Hallet J, Singh S, ...
Keywords: TAMIS